RGNX: 30% | REGENXBIO shares are trading higher after the company announced dosing the first patient in its pivotal trial for Duchenne gene therapy.

NIVF: 123% | NewGenIvf Inks Binding Term Sheet With California-Based Institutional Investor White Lion Capital, LLC, For $100M Equity Line Of Credit, Expandable To $500M

ALDX: 10% | Aldeyra Therapeutics shares are trading higher after the FDA accepted its resubmitted new drug application for Reproxalap for the treatment of dry eye disease, prompting the company to announce an expansion of its option agreement with AbbVie.